p-value = 0.0057), as well as older age, ISS stage III, and distinct molecular variables such as del(13q)/RB1, 1q gain/amplification alone or in combination with TP53 alterations, t(4;14) translocation, MYC translocation, and the presence of DIS3 mutations; conversely, ISS stage I and HD cases showed a 56% and 34% progression risk reduction, respectively (Supplementary Figure S2). The gene discussed is MYC; the disease is Huntington disease.